stockrowRoivant Sciences Ltd. (ROIV) vs Vertex Pharmaceuticals Incorporated (VRTX)
- Roivant Sciences Ltd. ROIV 38.79 +5.93%
- Vertex Pharmaceuticals Incorporated VRTX 547.11 +0.85%
Roivant Sciences Ltd. and Vertex Pharmaceuticals Incorporated are both Biotechnology companies. Vertex Pharmaceuticals Incorporated is the larger, with a market value of $137.5B against $26.5B — 5.2× the size. Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; Vertex Pharmaceuticals Incorporated trades at 34.6×. Vertex Pharmaceuticals Incorporated grew revenue faster over the last twelve months: 10.5% against −67.6%. Vertex Pharmaceuticals Incorporated has the higher net margin (30.7% vs −3,535.0%) and the higher return on invested capital (14.9% vs −34.5%). Across the 19 metrics below, Vertex Pharmaceuticals Incorporated leads on 16 and Roivant Sciences Ltd. on 3.
Valuation
Profitability
| Metric | ROIV | VRTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 81.21% | 85.53% | 65.16% |
| Operating margin | (7,914.75%) | 33.23% | 0.00% |
| Net margin | (3,534.96%) | 30.70% | 0.00% |
| Free cash flow margin | (10,901.00%) | 24.73% | 0.00% |
| Return on equity | (5.47%) | 20.80% | (50.12%) |
| Return on assets | (5.15%) | 13.81% | (45.60%) |
| Return on invested capital | (34.51%) | 14.86% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack